

Reference Data

1st Quarter - Fiscal Year 2018
(April 1, 2018 to June 30, 2018)

Consolidated Earnings

• Consolidated Financial Data	P 1
• Consolidated Balance Sheets	P 2
• Consolidated P/L Statement	P 3
• Consolidated Sales Breakdown by Segment/Category	P 4
• Consolidated Operating Income by Segment	P 4
• Consolidated Sales - Leading Brands of Self-Medication Operations	P 5
• Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations	P 6
• Capital Expenditure	P 7
• Depreciation and Amortization	P 7
• R&D Expenses	P 7
• Results of Major Consolidated Subsidiaries	
♦ Taisho Pharmaceutical	P 8
♦ Taisho Toyama Pharmaceutical	P 8
♦ Biofermin Pharmaceutical	P 8
• Major Subsidiaries and Affiliates	P 9
• Prescription Pharmaceutical Operations:	
New Drug Development-Taisho Pharmaceutical	P10
• Launch of New Products	P12

Consolidated Financial Data

(Millions of yen)

	March 2018(FY2017)				March 2019(FY2018)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Net sales	68,532	138,630	215,798	280,092	61,748	132,000	269,000
(YOY%)	(-1.3%)	(-1.7%)	(-0.3%)	(+0.1%)	(-9.9%)	(-4.8%)	(-4.0%)
Self-Medication operations	44,823	91,876	140,853	183,996	42,491	91,100	186,500
Prescription Pharmaceutical operations	23,709	46,753	74,944	96,096	19,257	40,900	82,500
Gross profit*	44,300	89,559	140,698	182,984	40,547	86,300	176,400
Selling, general and administrative expenses	37,358	74,380	112,143	146,007	32,389	72,300	143,400
Research and development expenses (% Sales)	5,291 (7.7%)	10,771 (7.8%)	15,539 (7.2%)	21,150 (7.6%)	4,376 (7.1%)	10,800 (8.2%)	21,100 (7.8%)
Advertising expenses	5,975	11,338	18,565	22,579	4,277	10,500	20,900
Sales promotion expenses	7,307	14,362	21,992	28,636	6,218	14,400	28,900
Personnel expenses	8,874	17,770	26,610	35,241	8,598	17,300	33,800
Operating income	6,941	15,178	28,555	36,977	8,157	14,000	33,000
(YOY%)	(-23.8%)	(-8.9%)	(+7.5%)	(+15.7%)	(+17.5%)	(-7.8%)	(-10.8%)
Ordinary income	8,796	17,850	33,379	42,140	12,205	16,500	39,500
(YOY%)	(-15.6%)	(-6.7%)	(+6.4%)	(+10.8%)	(+38.8%)	(-7.6%)	(-6.3%)
Profit attributable to owners of parent	5,534	12,016	26,463	31,679	13,689	39,000	55,500
(YOY%)	(-20.3%)	(-11.0%)	(+11.8%)	(+10.1%)	(+147.3%)	(+224.6%)	(+75.2%)
Comprehensive income	10,303	20,452	36,625	36,627	12,587	-	-
(YOY%)	(+198.2%)	(+284.6%)	(+92.8%)	(+21.3%)	(+22.2%)	-	-
Basic EPS (yen)	69.27	150.38	331.19	396.54	171.50	488.10	694.62
Diluted EPS (yen)	69.21	150.26	330.92	396.20	171.35	487.67	693.99
BPS (yen)	8,189.49	8,313.96	8,458.68	8,452.12	8,542.77	8,815.40	8,972.94
Dividend per share (yen)	-	50.00	-	110.00	-	50.00	110.00
Payout ratio	-	-	-	27.7%	-	-	15.8%
Capital expenditure	685	1,999	2,951	4,857	733	1,820	6,270
Depreciation and amortization	2,474	4,972	7,525	10,154	2,438	4,930	10,210
Total assets	778,999	791,947	806,269	799,616	795,842	836,000	843,000
Shareholders' equity	669,809	680,053	692,066	691,318	694,483	721,000	734,000
Return on equity (%)**	-	-	-	4.8%	-	-	8.0%
Return on assets (%)**	-	-	-	4.0%	-	-	6.8%
Equity ratio (%)	84.0%	83.9%	83.8%	84.4%	85.7%	84.3%	85.0%
Overseas sales	8,283	15,988	23,500	30,936	7,849	15,600	32,510
Overseas sales ratio (% of total sales)	12.1%	11.5%	10.9%	11.0%	12.7%	11.8%	12.1%
Number of employees	6,525	6,484	6,412	6,340	6,305	-	-

* After provision/reversal of reserve for returned unsold goods

** Average of the beginning and year-end balance of shareholders' equity / total assets

*** The figures for the preceding fiscal year have been revised retrospectively following the partial revision to the Accounting Standards for Tax Effect Accounting.

<Reference>

• E = Estimates

• The 2Q forecasts (previous) for the fiscal year ending March 31, 2019 were announced on May 14, 2018.

Consolidated Balance Sheets

(Millions of yen)

	End of FY2017 *1		End of FY2018/1Q		change	
	(March 31, 18)	% total	(Jun. 30, 18)	% total		
(Assets)						
I Current assets:	356,161	44.5%	356,556	44.8%	+394	
Cash and deposits	219,973		217,712		-2,261	
Notes and accounts receivable-trade	75,268		69,262		-6,005	
Marketable securities	29,739		29,570		-168	
Inventories	26,844		28,693		+1,849	
Other	4,335		11,317		+6,981	
II Fixed assets:	443,455	55.5%	439,286	55.2%	-4,168	
(1) Tangible fixed assets:	93,716	(11.7%)	92,742	(11.7%)	-973	
Buildings and structures	47,536		46,908		-628	
Machinery, equipment and vehicles	5,449		5,378		-71	
Land	37,021		37,022		+1	
Other	3,708		3,433		-275	
(2) Intangible fixed assets:	31,116	(3.9%)	30,060	(3.8%)	-1,056	
Goodwill	15,347		15,022		-325	
Sales rights	2,740		2,410		-330	
Trademarks	8,750		8,392		-358	
Software	3,627		3,596		-31	
Other	650		639		-11	
(3) Investments and other assets:	318,622	(39.8%)	316,483	(39.8%)	-2,139	
Investment securities	236,797		237,681		+883	
Shares of subsidiaries and affiliates	65,294		62,119		-3,174	
Net defined benefit assets	3,230		3,300		+70	
Deferred tax assets	11,806		11,971		+164	
Other	1,492		1,409		-82	
Total assets	799,616	100.0%	795,842	100.0%	-3,773	
(Liabilities)						
I Current liabilities:	60,299	7.5%	58,480	7.3%	-1,819	
Notes and accounts payable-trade	19,939		18,616		-1,323	
Accounts payable	14,275		17,060		+2,785	
Accrued income tax	8,614		3,511		-5,102	Decline after payment
Provision for bonuses	3,874		1,963		-1,911	
Other	13,595		17,329		+3,733	
II Long-term liabilities:	47,998	6.0%	42,878	5.4%	-5,119	
Net defined benefit liabilities	23,391		23,486		+94	
Deferred taxes liabilities	16,970		11,924		-5,046	
Other	7,637		7,468		-168	
Total liabilities	108,298	13.5%	101,359	12.7%	-6,938	
(Net assets)						
I Shareholders' equity	643,655	80.5%	652,334	82.0%	+8,678	
Common stock	30,000	3.8%	30,000	3.8%	-	
Capital surplus	15,271	1.9%	15,081	1.9%	-190	
Retained earnings	666,920	83.4%	675,816	84.9%	+8,895	Profit attributable to owners of parent +13,689 Dividend on retained earnings ▲4,793
Treasury stock	-68,536	-8.6%	-68,563	-8.6%	-26	
II Accumulated other comprehensive income	31,009	3.9%	29,545	3.7%	-1,463	
Valuation difference on securities	37,970	4.7%	38,640	4.9%	+670	
Deferred gains or losses on hedges	-0	-0.0%	-	0.0%	+0	
Foreign currency translation adjustment	-1,704	-0.2%	-3,909	-0.5%	-2,204	
Remeasurements of defined benefit plans	-5,256	-0.7%	-5,185	-0.7%	+70	
III Subscription rights to shares	565	0.1%	565	0.1%	-	
IV Non-controlling interests	16,087	2.0%	12,037	1.5%	-4,050	
Total net assets	691,318	86.5%	694,483	87.3%	+3,165	
Total liabilities and net assets	799,616	100.0%	795,842	100.0%	-3,773	

*1 The figures for the preceding fiscal year have been revised retrospectively following the partial revision to the Accounting Standards for Tax Effect Accounting.

Consolidated P/L Statement

(Millions of yen)

	FY2017		FY2018		YOY change	
	1Q	% total	1Q	% total		
Net sales	68,532	100.0%	61,748	100.0%	-6,783	
Cost of sales	24,232	35.4%	21,295	34.5%	-2,937	
Gross profit on sales	44,299	64.6%	40,453	65.5%	-3,846	
Provision for sales returns	-0		-93		-92	
Gross profit	44,300	64.6%	40,547	65.7%	-3,753	
Selling, general and administrative expenses	37,358	54.5%	32,389	52.5%	-4,969	
Research and development expenses	5,291		4,376		-915	
Advertising expenses	5,975		4,277		-1,697	
Sales promotion expenses	7,307		6,218		-1,088	
Personnel expenses	8,874		8,598		-275	
Other	9,911		8,918		-992	
Operating income	6,941	10.1%	8,157	13.2%	+1,215	
Non-operating income	2,241	3.3%	4,072	6.6%	+1,831	Equity in earnings of entities accounted for using equity method:1,361
Non-operating expenses	386	0.6%	24	0.0%	-361	(FY2017)Equity in losses of entities accounted for using equity method:361
Ordinary income	8,796	12.8%	12,205	19.8%	+3,408	
Extraordinary gains	742	1.1%	0	0.0%	-742	Gain on sale of investment securities: -742
Extraordinary losses	9	0.0%	1	0.0%	-7	
Income before income taxes and minority interests	9,529	13.9%	12,203	19.8%	+2,674	
Income taxes	3,478	5.1%	-1,889	-3.1%	-5,368	Decrease in income taxes - deferred after the resolution to sell stock of Toyama Chemical Co., Ltd.
Profit	6,050	8.8%	14,093	22.8%	+8,042	
Profit attributable to non-controlling interests	515	0.8%	403	0.7%	-111	
Profit attributable to owners of parent	5,534	8.1%	13,689	22.2%	+8,154	

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2018(FY2017)				March 2019(FY2018)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Self-Medication operations (YOY%)	44,823 (+4.2%)	91,876 (+1.6%)	140,853 (+1.9%)	183,996 (+2.2%)	42,491 (-5.2%)	91,100 (-0.8%)	186,500 (+1.4%)
Japan	35,949	74,513	115,263	150,191	34,016	74,200	151,000
Overseas	8,281	15,979	23,489	30,921	7,747	15,600	32,500
Other	592	1,383	2,099	2,884	726	1,300	3,000
Prescription Pharmaceutical operations (YOY%)	23,709 (-10.3%)	46,753 (-7.5%)	74,944 (-4.2%)	96,096 (-3.7%)	19,257 (-18.8%)	40,900 (-12.5%)	82,500 (-14.1%)
Ethical drugs	22,732	45,221	70,727	91,259	18,253	39,600	80,700
Other	976	1,531	4,217	4,837	1,003	1,300	1,800
Total	68,532	138,630	215,798	280,092	61,748	132,000	269,000

Consolidated Operating Income by Segment

(Millions of yen)

	March 2018(FY2017)				March 2019(FY2018)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Self-Medication operations (YOY%)	5,843 (-16.8%)	14,311 (-5.9%)	22,216 (-2.3%)	30,162 (+0.2%)	7,574 (+29.6%)	14,700 (+2.7%)	32,800 (+8.7%)
Prescription Pharmaceutical operations (YOY%)	1,414 (-43.3%)	1,563 (-31.2%)	7,396 (+48.5%)	8,207 (+144.8%)	906 (-35.9%)	0 (-100.0%)	1,700 (-79.3%)
Other* (YOY%)	-316 (-)	-696 (-)	-1,058 (-)	-1,393 (-)	-323 (-)	-700 (-)	-1,500 (-)
Total	6,941	15,178	28,555	36,977	8,157	14,000	33,000

* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of Yen)

	March 2018(FY2017)				March 2019(FY2018)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Japan	359	745	1,153	1,502	340	-5.4%	742	1,510	+0.5%
Lipovitan series	146	310	441	547	133	-9.2%	303	543	-0.7%
Pabron series	46	114	209	289	51	+10.8%	115	286	-1.0%
RiUP series	37	78	123	165	34	-8.3%	78	160	-3.2%
Biofermin series	24	36	65	86	24	+1.8%	45	94	+8.4%
VICKS series	5	15	31	40	6	+27.2%	15	41	+1.8%
Gastrointestinal treatment series	9	18	30	39	8	-8.9%	18	38	-2.4%
Livita series	9	17	26	35	8	-8.3%	16	36	+1.2%
Colac series	9	16	25	33	7	-21.1%	17	32	-3.3%
NARON series	7	15	24	32	7	-4.0%	15	31	-1.8%
Overseas	83	160	235	309	77	-6.4%	156	325	+5.1%
Energy drinks	28	56	85	108	30	+6.4%	58	116	+6.8%
OTC drugs	51	95	138	186	42	-18.3%	90	195	+5.0%
Others	6	14	21	29	7	+22.7%	13	30	+4.0%

(Rounded to the nearest hundred-million)

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2018(FY2017)				March 2019(FY2018)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Lipovitan series	146	310	441	547	133	-9.2%	303	543	-0.7%
Lipovitan D	95	201	287	353	86	-9.7%	199	353	+0.1%
Others	51	109	154	195	47	-8.2%	104	190	-2.3%
(100mL other Lipovitans)	34	72	101	127	32	-6.5%	69	126	-0.8%
(50mL other Lipovitans)	17	37	54	68	15	-11.5%	36	65	-5.0%

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of Yen)

	March 2018(FY2017)				March 2019(FY2018)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	2Q E (4-9)	YOY
Edirol	62	124	192	254	59	-4.6%	128	260	+2.4%
Bonviva	16	32	49	65	14	-8.7%	34	73	+12.3%
Lusefi	12	21	36	50	11	-7.7%	30	65	+30.8%
ZOSYN	28	53	79	98	15	-46.8%	28	48	-50.9%
Clarith	19	34	58	77	12	-37.2%	21	46	-39.9%
LOQOA	8	16	24	31	8	+2.6%	20	45	+47.5%
Biofermin	12	21	32	40	11	-2.6%	20	40	+0.4%
Palux	13	25	38	49	9	-31.6%	18	34	-30.1%
Geninax	2	20	33	44	2	-4.4%	15	35	-20.6%
OZEX	9	17	29	36	6	-34.0%	11	24	-33.5%

(Rounded to the nearest hundred-million)

Consolidated: Capital Expenditure

(Millions of yen)

	March 2018(FY2017)				March 2019(FY2018)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Total capital expenditure	685	1,999	2,951	4,857	733	1,820	6,270
Taisho Pharmaceutical	539	1,765	2,424	4,054	492	1,140	4,450
Production department	195	524	803	1,331	101	430	1,230
Research department	209	562	678	1,084	114	200	660
Head Office and the others	134	678	941	1,638	275	510	2,560
Other subsidiaries	145	233	527	803	241	680	1,820

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2018(FY2017)				March 2019(FY2018)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Depreciation and amortization	2,474	4,972	7,525	10,154	2,438	4,930	10,210
Cost of sales	751	1,503	2,275	3,085	751	1,580	3,330
SGA expenses	1,722	3,468	5,249	7,068	1,687	3,350	6,880

Consolidated: R&D Expenses

(Millions of yen)

	March 2018(FY2017)				March 2019(FY2018)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Total R&D expenses	5,291	10,771	15,539	21,150	4,376	10,800	21,100
Self-Medication operations	1,495	3,107	4,443	5,983	1,263	3,200	6,000
Prescription Pharmaceutical operations	3,796	7,664	11,095	15,167	3,113	7,600	15,100

Results of Major Consolidated Subsidiaries

Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 2018(FY2017)				March 2019(FY2018)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Net Sales	493	1,005	1,582	2,052	454	-7.9%	982	2,007	-2.2%
Self-Medication	364	756	1,167	1,519	346	-4.8%	752	1,529	+0.6%
Prescription Pharmaceutical	129	250	415	532	107	-16.8%	230	478	-10.2%
Operating income	38	100	201	259	54	+42.9%	99	236	-8.8%
Ordinary income	79	171	279	336	83	+5.4%	170	312	-7.3%
Profit	61	136	241	282	65	+5.9%	128	236	-16.4%

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical

(Billions of Yen)

	March 2018(FY2017)				March 2019(FY2018)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Net Sales	227	452	707	913	183	-19.7%	396	807	-11.6%
Operating income	4	14	23	27	2	-51.4%	9	19	-30.1%
Ordinary income	4	14	23	27	2	-50.4%	9	19	-29.9%
Profit	2	9	15	17	1	-61.8%	6	12	-31.1%

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical are included in the consolidated results of Prescription Pharmaceutical operations.

Sales and earnings of Biofermin Pharmaceutical

(Billions of Yen)

	March 2018(FY2017)				March 2019(FY2018)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Net Sales	30	59	85	109	29	-3.7%	54	110	+1.4%
Self-Medication	20	40	56	74	19	-5.3%	36	75	+1.9%
Prescription Pharmaceutical	11	19	28	35	10	-0.6%	18	35	+0.3%
Operating income	11	19	26	32	11	-1.9%	17	33	+2.4%
Ordinary income	11	19	26	31	11	-1.3%	17	33	+5.5%
Profit	8	13	18	22	8	-0.9%	12	23	+4.1%

(Rounded to the nearest hundred-million)

Major Subsidiaries and Affiliates

(As of June 30, 2018)

Company	Address	Capital	Business	Ownership [*]
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co., Ltd.	Tokyo, Japan	,000 Yen 29,804,450	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co., Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co., Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co., Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	63.9
Taisho Toyama Pharmaceutical Co., Ltd.	Tokyo, Japan	,000 Yen 2,000,000	PD	70.3
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Dr. Program Co., Ltd.	Tokyo, Japan	,000 Yen 251,500	SMG	100.0
Taisho Pharmaceutical (Taiwan) Co., Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co., Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co., Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 165,300	SMG	100.0
Osotspa Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.6
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,000	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C	Mexico	,000 MXN 122,467	SMG	100.0
(2) Equity accounting method				
Toyama Chemical Co., Ltd.	Tokyo, Japan	,000 Yen 10,000,000	PD	34.0
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.1
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 1,307,460,710	SMG	24.9

*Ownership: including the portion of indirect ownership

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of Aug 1, 2018

In Japan

Filed for Application

Taurine powder 98% "Taisho"

< Application > Prevention of recurrence of stroke-like episodes for MELAS¹⁾
 ※Additional indication

< Development > In-house

¹⁾MELAS: Mitochondrial myopathy, Encephalopathy, Lactic Acidosis and Stroke-like episodes

Phase 3

TS-152 (Injection)

< Application > Rheumatoid arthritis

< Development > In-license (Licensor: Ablynx)

< Description > Anti-TNF(Tumor Necrosis Factor)- α antibody

< Remarks > Generic name: Ozoralizumab

Phase 2

TS-091 (Oral)

< Application > Central disorders of hypersomnolence

< Development > In-house

TS-141 (Oral)

< Application > Childhood Attention-Deficit/Hyperactivity Disorder

< Development > In-house

TS-133 (Topical)

< Application > Alopecia

< Development > In-house

TS-142 (Oral)

< Application > Insomnia

< Development > In-house

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of Aug 1, 2018

Overseas

Phase 2

TS-121 (Oral)

< Application > Depression
< Development > In-house

Phase 1

TS-071 (Oral)

< Target disease > Type 2 diabetes
< In-house/Licensed-in > In-house
< Description > Sodium-glucose cotransporter 2 (SGLT2) inhibitor
< Remarks > Generic name: Luseogliflozin Hydrate
In Japan: Launched on May 23, 2014 (Product name: Lusefi)

TS-091 (Oral)

< Target disease > Central disorders of hypersomnolence
< In-house/Licensed-in > In-house

TS-134 (Oral)

< Target disease > Schizophrenia
< In-house/Licensed-in > In-house

Launch of New Products

As of Aug 1, 2018

New Products Since FY2017 Earnings Announcement (Mar 14, 2018)

Self-Medication Operations

COBARASAPŌTO Fukurami plus Kiwifruit & Pineapple Flavors

- < Description > A diet support beverage that expands in volume after consumption when you feel hungry has evolved with our own technology to bolster the expansion to nearly 1.4 times to 2.0 times that of the existing model. The new models feature refreshing kiwifruit and pineapple flavors that are currently popular.
- < Launch > Since Jun 2018
-

Lipovitan D limited-edition Japanese professional baseball teams bottle

- < Description > The Lipovitan D label now features one of the mascots of the Nippon Professional Baseball teams. The design has been changed entirely from that for the previous season. A bottle featuring Yomiuri Giants has been introduced. Stocks and regions limited.
- < Launch > Since Jun 2018
-

RAIZIN SUMMER

- < Description > A new item in the RAIZIN series of new carbonated drink for business workers with a strong refreshing flavor associated with summer and with an exterior look based on white to represent the refreshing flavor. Stocks and time limited.
- < Launch > Since Jul 2018
-

Granular tablets for those concerned about their blood sugar level after eating

- < Description > Classified as a food with function claims, this product contains 0.2 mg of Salacia-derived salacinol per tablet as a function-related ingredient. Just one tablet should be taken before eating as a rough guide. As a highly convenient tablet, it can be easily consumed anywhere with water.
- < Launch > Since Jul 2018
-

Lipovitan D Kids in the *LupaPato* bottle

- < Description > A Lipovitan D Kids model sold in a limited quantity in a limited period in a special bottle in a tie-up with the *tokusatsu* super *sentai* television drama series, *Kaitou Sentai Lupinranger VS Keisatsu Sentai Patranger*. A compact caffeine-free energy drink that contains nutritional ingredients important to child growth, such as vitamins, calcium and taurine.
- < Launch > Since Jul 2018
-

Launch of New Products

As of Aug 1, 2018

New Products Since FY2017 Earnings Announcement (Mar 14, 2018)

Prescription Pharmaceutical Operations
--

OZEX® Tablet for Children 60 mg

- < Description > Developed exclusively for children as a tablet form of the OZEX new quinolone antibacterial, acquiring approval for manufacturing and sales in February 2018
- < Launch > Since Jul 2018
-